Navigation Links
DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
Date:2/12/2009

Phase 3 trial costs] that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 10-Q and 10-KSB. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.


'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
2. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
3. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
4. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
6. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
7. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
8. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
9. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
10. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a ... for two years, the longest of any cellulite reduction system currently on the market. ... effective solution for their cellulite, according to Dr. Robert Weiss, director of the premier ...
(Date:8/28/2015)... ... 28, 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based ... With A Mission” benefit concert in Mendon, IL. Held in the Show Barn at ... support music education programs in the underfunded local school districts of Mendon at neighboring ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL ... with zero fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 ... 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... documenting and diagramming network and data center assets and audio-video devices, recently released ... Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series , Super Micro ...
(Date:8/28/2015)... ... ... Medical Solutions, one of the nation’s largest travel nurse staffing companies, has ... Healthcare and will be honored at an awards dinner in Chicago on Wednesday, ... to Work in Healthcare program recognizes outstanding employers in the healthcare industry nationwide. Modern ...
Breaking Medicine News(10 mins):Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3
... but 24.6% of these are not based on any scientific ... at Baza Hospital (Granada), published in the journal BMC Public ... primary and secondary school text books in order to identify ... classified them into three categories messages with a high, ...
... common practices of health care providers who see adolescent ... clinician and researcher at Women & Infants Hospital of ... an adolescent medicine specialist at Hasbro Children,s Hospital, asserted ... for teenagers who are sexually active. This includes ...
... HealthDay Reporter , THURSDAY, March 24 (HealthDay News) ... into the world of viable treatments, scientists have successfully fashioned ... fall victim to the onset of age-related macular degeneration, or ... which have been the subject of much debate in recent ...
... , This press release is available in French ... of Optics of the University of Granada , belonging to ... a programme for testing alterations in night vision, and the tool ... instrument consists on a software named Software Halo v1.0, and a ...
... Helena Johansson, Research fellow at the Centre for Bone ... Dr. Maria-Belen Zanchetta, Research fellow at the Instituto de ... the winners of the 2011 ESCEO-AMGEN Fellowship. ... Aspects of Osteoporosis and Osteoarthritis (ESCEO) with support from ...
... PA, March 23, 2011 Although acupuncture is commonly ... safety remain. Investigators from the Universities of Exeter & ... Medicine (Daejeon, South Korea) critically evaluated systematic reviews of ... explore this question. Reporting in the April 2011 issue ...
Cached Medicine News:Health News:Around 25 percent of health messages in Spanish text books are not based on scientific evidence 2Health News:Researchers: Sexually active teens need confidential health care 2Health News:Researchers: Sexually active teens need confidential health care 3Health News:Progress Seen in Creating Eye Cells From Stem Cells 2Health News:Progress Seen in Creating Eye Cells From Stem Cells 3Health News:Researchers develop a halometer that tests alterations in night vision 2Health News:Researchers develop a halometer that tests alterations in night vision 3Health News:Acupuncture for pain no better than placebo and not without harm 2
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
(Date:8/28/2015)... August 28, 2015 According to ... Tumor (Breast, Lung, Prostate) Type (Protein & Genetic Biomarkers) ... Discovery, Prognostic) & Geography - Global Forecast to 2020", ... to reach around 17,689.0 Million USD by 2020 at ... 2015 to 2020. Browse 191 Tables ...
(Date:8/28/2015)... Research and Markets ... the "12th Annual Report and Survey of ... their offering. The 2015 12th Annual ... Production is the most recent study of biotherapeutic ... future capacity and production. The report contains the ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... NEW YORK, Jan. 28, 2011 Get content ... http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=edb04e54-24b1-41bc-b1f7-aac03a4e0b31&lr=ls British Prime Minister David ... double its current contribution to polio eradication. Mr. ... Global Polio Eradication Initiative as he announced the ...
... 28, 2011 Drug safety remains front and center ... agency strives to improve the public,s perception of the ... its reputation among consumers and recognizes that its diligence ... role in that effort. One issue that ...
Cached Medicine Technology:Navigating the Gray Areas of Post-Marketing Surveillance 2
Rees bayonet forceps, standard, 5-1/2", TC....
... Channel Implants, designed to accept ... surgeon with an excellent reconstructive ... and floor blowout defects. Each ... placement of one or more ...
... is designed to augment areas ... midface, including the inferior orbital ... in the hollow under the ... implant aids in restoring the ...
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig...
Medicine Products: